Bicara Therapeutics (NASDAQ:BCAX) Stock Gets Price Target Cut from BTIG Research

Bicara Therapeutics (NASDAQ:BCAX) had its price objective lowered by BTIG Research from $39.00 to $37.00 in a report published on Tuesday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other brokerages have also recently commented on BCAX. The Goldman Sachs Group cut shares of Bicara Therapeutics from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $20.00 to $8.00 in a research report on Friday, October 30th. BMO Capital Markets initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research note on Thursday, September 10th. HSBC downgraded Bicara Therapeutics to an “equal weight” rating in a report on Tuesday, September 22nd. Finally, Morgan Stanley reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Tuesday, October 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $30.33.

Bicara Therapeutics Price Performance

BCAX stock opened at $10.11 on Tuesday. Bicara Therapeutics has a one year low of $7.87 and a one year high of $30.99. The company’s 50 day moving average price is $17.10 and its two-hundred day moving average price is $20.81.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). As a group, analysts anticipate that Bicara Therapeutics will post -3.82 earnings per share for the current year.

Insider Activity

In related news, CEO Ryan Cohlhepp sold 17,500 shares of Bicara Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total value of $400,750.00. Following the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. The trade was a 8.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its holdings in Bicara Therapeutics by 457.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock worth $26,000 after acquiring an additional 1,138 shares during the last quarter. Profund Advisors LLC increased its position in shares of Bicara Therapeutics by 7.2% in the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock valued at $314,000 after acquiring an additional 1,140 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicara Therapeutics by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock valued at $224,000 after acquiring an additional 1,617 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Bicara Therapeutics by 16.1% during the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after acquiring an additional 2,447 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the third quarter valued at about $63,000.

Key Headlines Impacting Bicara Therapeutics

These are some of the BCAX headlines that stood out recently:

• Positive Sentiment: HC Wainwright kept its Buy rating on BCAX and a $36 price target, which could support investor optimism despite the target reduction from $42. HC Wainwright target update
• Negative Sentiment: Stifel Nicolaus and Morgan Stanley reportedly cut their BCAX price targets, and BTIG Research issued a pessimistic forecast. These actions may weigh on sentiment; the provided headlines do not specify the revised targets or detailed rationale. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright’s 2027 estimates project continuing quarterly losses, including a full-year loss of $4.63 per share. Expectations of ongoing losses can be a headwind for a clinical-stage biotech, even with the firm’s Buy rating.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.